Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Book Value Per Share 3 year CAGR for the Trailing 12 Months (TTM) ending January 31, 2024: -13.47%

Kalvista Pharmaceuticals Inc Book Value Per Share 3 year CAGR is -13.47% for the Trailing 12 Months (TTM) ending January 31, 2024, a -639.33% change year over year. The book value per share represents the net value of a company allocated to each outstanding share of common stock. It is calculated by dividing shareholders' equity by the weighted average number of shares outstanding. The book value per share provides insight into the intrinsic value of a company's shares and can be used to assess the relative value of a stock compared to its market price. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Kalvista Pharmaceuticals Inc Book Value Per Share for the Trailing 12 Months (TTM) ending January 31, 2023 was 5.19, a -46.65% change year over year.
Kalvista Pharmaceuticals Inc Book Value Per Share for the Trailing 12 Months (TTM) ending January 31, 2022 was 9.73, a 147.15% change year over year.
Kalvista Pharmaceuticals Inc Book Value Per Share for the Trailing 12 Months (TTM) ending January 31, 2021 was 3.94, a -28.23% change year over year.
Kalvista Pharmaceuticals Inc Book Value Per Share for the Trailing 12 Months (TTM) ending January 31, 2020 was 5.49, a 21.46% change year over year.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends